Results 341 to 350 of about 22,374,088 (435)

Extracellular vesicles in multiple myeloma: pathogenesis and therapeutic application

The FEBS Journal, EarlyView.
Multiple myeloma is characterised by the clonal proliferation of plasma cells in the bone marrow. Extracellular vesicles (EVs) are a key component of cell‐to‐cell communication within the bone marrow microenvironment, promoting tumour growth, bone remodelling, immune modulation, angiogenesis and therapeutic resistance.
Chloe Wylie, Rebecca Rowan, Dessi Malinova, Lisa Crawford   +3 more
wiley   +1 more source

Analysis of chromosomes in molecular tumor and radiation cytogenetics: Approaches, apllications, perspectives [PDF]

, 1992
Cremer, Christoph, Cremer, Thomas
core  

Liquid Biopsy for Enhanced Specificity in Identifying Somatic Mutations in Aggressive Non‐Hodgkin Large B‐Cell Lymphoma: A Comparative Study of Cell‐Free DNA and Formalin‐Fixed Paraffin‐Embedded Tissue

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Formalin‐fixed paraffin‐embedded (FFPE) tumor biopsy is the current mainstay of genotyping, but is limited by its invasiveness and tumor heterogeneity. Plasma cell‐free DNA (cfDNA) constitutes a minimally invasive alternative that may better capture tumor‐derived profiles from circulating tumor DNA (ctDNA). This study compares the
Gayaththri Vimalathas, Oriane Cédile, Marie Louise Grube Kjeldsen, Mads Thomassen, Michael Boe Møller, Charlotte Guldborg Nyvold, Marcus Høy Hansen, Thomas Stauffer Larsen   +7 more
wiley   +1 more source

Next Generation Sequencing Identifies Subgroups of Patients With Triple Negative Primary Thrombocytosis With Different Clinical Thrombotic Outcomes

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction The majority of patients with essential thrombocythemia (ET) show somatic mutations of JAK2, CALR, or MPL. Around 10% of cases lack these mutations (“triple negative” ET, TN‐ET). Additionally, some patients with bona fide “primary thrombocytosis” (PT) [i.e., high platelet (PLT)‐ count with no apparent underlying causes] do not ...
Valentina Sangiorgio, Federica Mottadelli, Fabio Pagni, Fabrizio Cavalca, Giovanni Cazzaniga, Martina Venegoni, Carlo Gambacorti‐Passerini, Rocco Piazza, Elena Maria Elli   +8 more
wiley   +1 more source

A new era in myeloma: the advent of chimeric antigen receptor‐T (CAR‐T) cells and bispecific antibodies

Internal Medicine Journal, Volume 55, Issue 5, Page 714-721, May 2025.
Abstract T‐cell re‐directional therapies, including chimeric antigen receptor (CAR)‐T cell and bispecific antibodies (BsA), have transformed the treatment landscape to benefit patients with multiple myeloma. A number of these novel therapies has been approved internationally, with CAR‐T therapy recently approved in Australia.
P. Joy Ho, Eric W. Li
wiley   +1 more source

Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach

Internal Medicine Journal, Volume 55, Issue 5, Page 749-759, May 2025.
Abstract Background After pharmaceutical benefits scheme approval of midostaurin for fms‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukaemia (AML) in 2018, the Australasian Leukaemia & Lymphoma Group (ALLG) proposed a consensus approach to AML induction with 7+3 chemotherapy (7 days of infusional cytarabine with three doses of anthracycline ...
Aditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, George Grigoriadis, Shaun Fleming, Shahla Vilcassim, Pasquale L. Fedele, Michael Sze Yuan Low, Paul Yeh, Michael Gilbertson, Ashwini Bennett, Gareth P. Gregory, Danielle Oh, Donna Gairns, Zane Kaplan, Sanjeev D. Chunilal, Susan Brown, Stephen Opat, Chong C. Chua, Jake Shortt   +19 more
wiley   +1 more source

Filling the gaps to empower regional centres to manage myelodysplastic syndrome and acute myeloid leukaemia leading to wider cancer healthcare delivery and access to clinical trials

Internal Medicine Journal, Volume 55, Issue 5, Page 722-727, May 2025.
Abstract Background The management of patients with haematological malignancies in rural and regional Australia is different to that in metropolitan centres due to many factors. Lower‐intensity and easier‐to‐access treatments that are now available for acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) have improved the deliverability of ...
Michael Ashby, Shaun Fleming, Andrew Spencer, Anne Woollett, Tricia Wright   +4 more
wiley   +1 more source

Detection of a Lymphoproliferative Disorder With Suspected Scattergram Analysis Using the Mindray BC‐6800 Plus Automated Hematology Analyzer: A Case Report

International Journal of Laboratory Hematology, Volume 47, Issue 3, Page 373-375, June 2025.
Sara Sacchetti, Matteo Bellia, Valentina Zanotti, Luca Giacomini, Roberta Rolla   +4 more
wiley   +1 more source

Acute Myeloid Leukaemia With Morphologic and Immunophenotypic Differentiation to Acute Erythroid Leukaemia at the Time of Relapse

International Journal of Laboratory Hematology, Volume 47, Issue 3, Page 380-381, June 2025.
Katie Liston, Vitaliy Mykytiv
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The Micronucleus Test for Cytogenetic Analysis

1976
Micronuclei originate from chromatin which for different reasons has been lagging in anaphase (Fig. la-d). In the course of telophase this material is included into one or the other daughter cell where it either can fuse with the main nucleus or form one or several secondary nuclei.
W. Schmid
openaire   +3 more sources